Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 29, 2025Cancer Research

Abstract B047: DNA Damage Repair (DDR) Variants Beyond BRCA/PALB2 in Pancreatic Adenocarcinoma (PDAC): Evaluation of Significance

View Full Paper
Ask AI
Bookmark
Share

Authors

COCatherine O’ConnorJLJonathan W. LeeEHEmily Harrold

Discussion

Loading...

Member takes

Overview

Analysis highlights germline pathogenic variants in PDAC, suggesting implications for treatment approaches and survival rates.

Key Points

  • Approximately 10–20% of PDAC patients harbor germline pathogenic variants in the DNA damage repair pathway.
  • Median overall survival was significantly different, with stage II patients averaging 40 months compared to stage IV at only 14 months.
  • Marked variability in progression-free survival was noted across treatment regimens, especially in the stage IV cohort.
  • Rare biallelic loss of DDR genes was identified; however, MUTYH gPV showed potential association with improved prognosis.

Cite This Study

O’Connor et al. (2025) studied this question.

synapsesocial.com/papers/68da58d8c1728099cfd10ed6https://doi.org/10.1158/1538-7445.pancreatic25-b047
View Full Paper
Ask AI
Bookmark
Share